Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies.
about
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indicationsImmunomodulatory antibody therapy of cancer: the closer, the betterClassification of current anticancer immunotherapiesInhibition of Tumor Growth and Immunomodulatory Effects of Flavonoids and Scutebarbatines of Scutellaria barbata D. Don in Lewis-Bearing C57BL/6 Mice.Potent CD4+ T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition.Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy.Innate immune mediators in cancer: between defense and resistance.Basis for molecular diagnostics and immunotherapy for esophageal cancer.Curing tumor-bearing mice by shifting a Th2 to a Th1 anti-tumor response.Immune Mechanisms Are Major Players in CancerTreg depletion potentiates checkpoint inhibition in claudin-low breast cancer.Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression.Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.TUSC2 Immunogene Therapy Synergizes with Anti-PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic Kras-Mutant Mouse Lung Cancer Models.CD137-CRDI is not necessary in the role of contacting its natural ligand.The differentiation and plasticity of Tc17 cells are regulated by CTLA-4-mediated effects on STATs.Tumor Regression and Cure Depends on Sustained Th1 Responses
P2860
Q26996518-C38CFC26-0098-4D5B-ADEE-6936C5AEF214Q35142851-F7F72DC6-1C81-4ECA-9011-31F98C7B38AEQ35149637-4FC774CC-7742-4633-A8C4-70CB45E97FE9Q35612583-49549D43-1D7A-4D46-93FC-06AD04582C3BQ37706213-84BB04DF-6948-41FB-9377-E7F3B5B6F190Q38698632-9DD9E954-BDD0-4E04-86E7-1B2DF2E0EC08Q38991015-89B9CFF9-F08C-406B-9E6E-B9ED2297A445Q39006844-511CA30F-3049-40DC-B7A2-91153206644BQ39022359-88E43995-58BA-4261-B3C0-ED2AE1AD28AEQ42534814-23A9DAEB-E228-484F-9363-96067EA61652Q47927802-B12450B9-3F1C-4C6A-A4CE-6F00B4387AFFQ47950137-85F51659-4CBA-4928-A576-119DE022EF93Q49432766-C42AE71E-5FA6-483B-953E-1B7468C2733BQ50020811-AD722829-A2EE-4138-8443-1EDB88DA85F5Q50783362-ADF64E9E-B3B7-4690-9A3F-634DF7157835Q51084408-717FD4D8-B7A7-4294-9F80-8A0E2379304BQ56876356-E2525DC7-E8B5-40BB-A614-81F7B854C252
P2860
Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Curing mice with large tumors ...... f immunomodulatory antibodies.
@ast
Curing mice with large tumors ...... f immunomodulatory antibodies.
@en
type
label
Curing mice with large tumors ...... f immunomodulatory antibodies.
@ast
Curing mice with large tumors ...... f immunomodulatory antibodies.
@en
prefLabel
Curing mice with large tumors ...... f immunomodulatory antibodies.
@ast
Curing mice with large tumors ...... f immunomodulatory antibodies.
@en
P2093
P2860
P1476
Curing mice with large tumors ...... f immunomodulatory antibodies.
@en
P2093
Ingegerd Hellstrom
Karl Erik Hellstrom
Yuen Yee Yip
P2860
P304
P356
10.1158/1078-0432.CCR-14-1339
P407
P577
2014-08-20T00:00:00Z